`OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL
`BOARD
`
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioner
`
`V.
`
`CIPLA LTD.
`
`Patent Owner
`
`Patent No. 8,168,620
`Issue Date: May 1, 2012
`Title: COMBINATION OF AZELASTINE AND STEROIDS
`
`
`
`Inter Partes Review No.: IPR2017-00807
`
`SUPPLEMENTAL DECLARATION OF
`ROBERTP. SCHLEIMER,Ph.D.
`
`000001
`
`Exhibit 1170
`IPR2017-00807
`
`ARGENTUM
`
`
`
`1.
`
`I submit this declaration as a supplement to my March 6, 2018 Second
`
`Declaration of Robert P. Schleimer, Ph.D. (Ex. 1144), in Support of Petitioner’s
`
`Reply to Patent Owner’s Response, and in responseto certain objections
`
`subsequently made by Cipla.
`
`2.
`
`Regarding Exhibit 1055 from the present proceeding, | saw this
`
`exhibit during the Cipla-Apotextrial, presented as a part of Defendant’s Exhibit
`
`DTX-002. Duringthat trial, I was an expert witness for Apotex.
`
`I heard Dr.
`
`Accetta testify that the document (submitted here as Ex. 1055) reproduces one of
`
`his patient records showing that he had co-prescribed Flonase and Astelin to the
`
`patient. The testimony from Dr. Accetta about this document that I heard appears
`
`in Patent Owner’s exhibit CIP2018 at 47:22-50:14, whichis the trial transcript
`
`from the Cipla-Apotextrial.
`
`3.
`
`In signing this declaration, I recognizethat the declaration will be
`
`served and/or filed as evidence in the present contested case before the Patent Trial
`
`and Appeal Board of the United States Patent and Trademark Office.
`
`I also
`
`recognize that I may be subject to cross-examination in the case andthat cross-
`
`examination will take place within the United States. If cross-examination is
`
`required of me, I will appear for cross-examination within the United States during
`
`the time allotted for cross-examination.
`
`i)
`
`000002
`
`
`
`4.
`
`I hereby declare that all statements made herein of my own
`
`knowledgeare true andthat all statements made on information and belief are
`
`believed to be true; and further that these statements were made with the
`
`knowledgethat willful false statements and the like so made are punishable by fine
`
`or imprisonment, or both, under Section 1001 of Title 18 of the United States
`
`Code.
`
`Nobat-Shanion
`
`Dated: March 27, 2018
`
`Robert P. Schleimer, Ph.D.
`
`